15+ Presentations from Top Pharma at Drug Discovery Chemistry Europe
DELete KRAS G12C: Covalent DNA-Encoded Library Screening Empowered the Discovery of a Structurally Novel, Potent, and CNS-penetrant KRAS G12C Inhibitor
Slavko Rast, PhD, Senior Principal Scientist, Amgen Research Copenhagen
ALOX15 Biology Interrogation with Small Molecules Enabled by DEL Screening
Garrick Paul Smith, PhD, Scientific Associate Director, Amgen
Unwinding Helicase Hit Discovery—An Affinity Solution
Alex Edwards, Senior Scientist, DNA Encoded Library Screening, AstraZeneca
Promises and Risks of Targeted Protein Degraders
Monica Rodrigo, PhD, Director, PROTAC Safety Sciences, Clinical Pharmacology & Safety Sciences, AstraZeneca
Fragment-Based Journey to the Clinic: Development of a Novel Oral PCSK9 Inhibitor with a Distinct Mechanism of Action
Stefan Geschwindner, PhD, Director, Biophysics, AstraZeneca R&D Gothenburg
Targeting the eIF4F Protein-mRNA Complex with Fragment-Based Approaches
Chiara R. Valenzano, PhD, Senior Research Associate, Molecular Science, Astex Pharmaceuticals
Enabling High-Throughput Electron Cryo-Microscopy for Structure-Based Design
David Norton, PhD, Director, Medicinal Chemistry, Astex Pharmaceuticals Ltd.
PK/PD-Model Guided Optimisation of Targeted Protein Degraders: Translating in vitro Data to in vivo Degradation Profiles
Andreas Reichel, PhD, Vice President & Head, DMPK Modelling & Simulations, Bayer Pharma AG
Hit Expansion and Lead Generation: C-H Functionalisation and Parallel Synthesis Enabled by High-Throughput Experimentation and Machine Learning Workflows
Alex Boddy, PhD, Scientist, Medicinal Chemistry, F. Hoffmann-La Roche Ltd.
Generative AI for Accelerated Lead Identification and Optimisation
Kenneth Atz, Small Molecule AI Scientist, Computer-Aided Drug Design CADD, F. Hoffmann-La Roche AG
The DELT Platform as an Efficient Lead Generation Strategy at Roche
Moreno Wichert, PhD, Principal Scientist, Small Molecule Research, F. Hoffmann-La Roche Ltd.
How Are AI Techniques Making an Impact on Preclinical Pharma?
(Panelist) Laura Perez Benito, Senior Scientist, Janssen Pharmaceutica NV
Harnessing Co-Folding for Drug Discovery: Identifying a Selective Cryptic Pocket in a Synthetic Lethality Oncology Target
Jose Carlos Gómez-Tamayo, Senior Scientist II, CADD, Johnson & Johnson Innovative Medicine
Disrupting the YAP-TEAD Protein-Protein Interaction with Small Molecules—Discovery of NVP-IAG933
Nicolas G. Soldermann, PhD, Director, Global Discovery Chemistry, Immuno-Oncology, Novartis Pharma SAS
Designing Proximity-Inducing Drugs: Emerging Principles & Opportunities
Ingo Hartung, PhD, Head, Medicinal Chemistry & Drug Design, Merck KGaA
YAP/TEAD PPI Disruption via Phenotypic-Derived in vivo Leads
Timo Heinrich, PhD, Associate Scientific Director, Oncology, Merck KGaA
How Are AI Techniques Making an Impact on Preclinical Pharma?
(Panelist) Marc Bianciotto, PhD, Drug Designer, Computer Aided Drug Design, Sanofi
How Are AI Techniques Making an Impact on Preclinical Pharma?
(Panelist) Anders Hogner, PhD, Associate Director, Medicinal Chemistry, AstraZeneca R&D